CN113330020B - 用于治疗神经变性疾病的2-氟代的胆汁酸 - Google Patents
用于治疗神经变性疾病的2-氟代的胆汁酸 Download PDFInfo
- Publication number
- CN113330020B CN113330020B CN201980085276.5A CN201980085276A CN113330020B CN 113330020 B CN113330020 B CN 113330020B CN 201980085276 A CN201980085276 A CN 201980085276A CN 113330020 B CN113330020 B CN 113330020B
- Authority
- CN
- China
- Prior art keywords
- compound
- dihydroxy
- difluoro
- formula
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1820887.6 | 2018-12-20 | ||
| GBGB1820887.6A GB201820887D0 (en) | 2018-12-20 | 2018-12-20 | Compounds |
| PCT/GB2019/053665 WO2020128514A1 (en) | 2018-12-20 | 2019-12-20 | 2-fluorinated bile acids for the treatment of neurodegenerative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113330020A CN113330020A (zh) | 2021-08-31 |
| CN113330020B true CN113330020B (zh) | 2024-04-05 |
Family
ID=65364420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980085276.5A Active CN113330020B (zh) | 2018-12-20 | 2019-12-20 | 用于治疗神经变性疾病的2-氟代的胆汁酸 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220073557A1 (https=) |
| EP (1) | EP3898645B1 (https=) |
| JP (1) | JP7503063B2 (https=) |
| KR (1) | KR102856276B1 (https=) |
| CN (1) | CN113330020B (https=) |
| AU (1) | AU2019411556B2 (https=) |
| BR (1) | BR112021011189A2 (https=) |
| CA (1) | CA3123333A1 (https=) |
| EA (1) | EA202191521A1 (https=) |
| ES (1) | ES3036094T3 (https=) |
| GB (1) | GB201820887D0 (https=) |
| IL (1) | IL284093B2 (https=) |
| MX (1) | MX2021007551A (https=) |
| SG (1) | SG11202105465WA (https=) |
| WO (1) | WO2020128514A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4486318A4 (en) * | 2022-03-02 | 2026-02-25 | Boyce Thompson Institute For Plant Res Inc | Cysteamides, related therapeutic compositions and associated processes |
| GB202208151D0 (en) | 2022-06-01 | 2022-07-13 | Nzp Uk Ltd | Compounds |
| GB202314563D0 (en) | 2023-09-22 | 2023-11-08 | Nzp Uk Ltd | Compounds |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014036379A2 (en) * | 2012-08-31 | 2014-03-06 | Metselex | Bile acids prevent or abolish progression of parkinson's and related neurodegenerative diseases |
| CN107531741A (zh) * | 2015-03-10 | 2018-01-02 | 美莱斯股份有限公司 | 氟化和烷基化胆酸 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ298567A (en) * | 1994-11-23 | 2000-01-28 | Cocensys Inc | Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| FR2934596B1 (fr) * | 2008-07-30 | 2015-04-10 | Trophos | Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation |
| ITMI20121344A1 (it) * | 2012-07-31 | 2014-02-01 | Erregierre Spa | Processo di preparazione di acido ursodesossicolico ad elevata purezza |
| CN103333216A (zh) * | 2013-06-04 | 2013-10-02 | 苏州大学 | 5α-6-酮-胆甾烷类似物及其应用 |
| US20150112089A1 (en) | 2013-10-22 | 2015-04-23 | Metselex, Inc. | Deuterated bile acids |
| GB201812382D0 (en) * | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
-
2018
- 2018-12-20 GB GBGB1820887.6A patent/GB201820887D0/en not_active Ceased
-
2019
- 2019-12-20 WO PCT/GB2019/053665 patent/WO2020128514A1/en not_active Ceased
- 2019-12-20 CA CA3123333A patent/CA3123333A1/en active Pending
- 2019-12-20 ES ES19831850T patent/ES3036094T3/es active Active
- 2019-12-20 AU AU2019411556A patent/AU2019411556B2/en active Active
- 2019-12-20 KR KR1020217019166A patent/KR102856276B1/ko active Active
- 2019-12-20 SG SG11202105465WA patent/SG11202105465WA/en unknown
- 2019-12-20 MX MX2021007551A patent/MX2021007551A/es unknown
- 2019-12-20 US US17/415,216 patent/US20220073557A1/en active Pending
- 2019-12-20 EP EP19831850.3A patent/EP3898645B1/en active Active
- 2019-12-20 CN CN201980085276.5A patent/CN113330020B/zh active Active
- 2019-12-20 JP JP2021535715A patent/JP7503063B2/ja active Active
- 2019-12-20 EA EA202191521A patent/EA202191521A1/ru unknown
- 2019-12-20 IL IL284093A patent/IL284093B2/en unknown
- 2019-12-20 BR BR112021011189-1A patent/BR112021011189A2/pt unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014036379A2 (en) * | 2012-08-31 | 2014-03-06 | Metselex | Bile acids prevent or abolish progression of parkinson's and related neurodegenerative diseases |
| CN107531741A (zh) * | 2015-03-10 | 2018-01-02 | 美莱斯股份有限公司 | 氟化和烷基化胆酸 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL284093B1 (en) | 2025-03-01 |
| EP3898645C0 (en) | 2025-06-25 |
| AU2019411556A1 (en) | 2021-06-10 |
| WO2020128514A1 (en) | 2020-06-25 |
| IL284093A (en) | 2021-08-31 |
| EP3898645B1 (en) | 2025-06-25 |
| GB201820887D0 (en) | 2019-02-06 |
| KR20210125982A (ko) | 2021-10-19 |
| EP3898645A1 (en) | 2021-10-27 |
| CN113330020A (zh) | 2021-08-31 |
| ES3036094T3 (en) | 2025-09-12 |
| BR112021011189A2 (pt) | 2021-08-31 |
| JP2022514401A (ja) | 2022-02-10 |
| AU2019411556B2 (en) | 2025-04-03 |
| MX2021007551A (es) | 2021-10-13 |
| EA202191521A1 (ru) | 2021-09-10 |
| IL284093B2 (en) | 2025-07-01 |
| CA3123333A1 (en) | 2020-06-25 |
| US20220073557A1 (en) | 2022-03-10 |
| JP7503063B2 (ja) | 2024-06-19 |
| SG11202105465WA (en) | 2021-06-29 |
| KR102856276B1 (ko) | 2025-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116370479B (zh) | 化合物atv014在制备用于治疗新冠病毒感染的产品中的用途 | |
| EP1728793B1 (en) | 9-substituted 8-oxoadenine compound | |
| CN113330020B (zh) | 用于治疗神经变性疾病的2-氟代的胆汁酸 | |
| JP2003507327A (ja) | 化学化合物 | |
| CN118451059A (zh) | 用于rna递送的可电离阳离子脂质 | |
| JP2022504697A (ja) | Ｓｓａｏ阻害剤とその使用 | |
| CN114805478A (zh) | 氘代拟肽类化合物及其用途 | |
| KR20190134722A (ko) | 치료 화합물 및 방법 | |
| CN121511234A (zh) | 用于rna递送的可电离阳离子脂质 | |
| CN116514902A (zh) | 氘代拟肽类化合物及其用途 | |
| JP2005527518A (ja) | 新規なカルコン（ｃｈａｌｃｏｎｅ）誘導体とその使用 | |
| JP2025518741A (ja) | ミトコンドリア機能関連疾患治療用の３－アザステロイド化合物 | |
| EP1277746B1 (fr) | Nouveaux dérivés de N-benzylpiperazine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| CN104860847A (zh) | 利凡斯的明和咖啡酸、阿魏酸的二聚体,其制备方法及其药物组合物 | |
| HK40062202A (en) | 2-fluorinated bile acids for the treatment of neurodegenerative diseases | |
| HK40062202B (en) | 2-fluorinated bile acids for the treatment of neurodegenerative diseases | |
| EA046372B1 (ru) | 2-фторированные желчные кислоты для лечения нейродегенеративных заболеваний | |
| CN113620967B (zh) | 一种α-倒捻子素衍生物及其制备方法和应用 | |
| JPH04505920A (ja) | 治療用ヌクレオシド | |
| HK40086425A (zh) | 秋水仙碱衍生物的制备方法及其用途 | |
| CN111138282A (zh) | 绿原酸l-精氨酸盐及其用途 | |
| CN110938001A (zh) | 绿原酸乙醇胺盐及用途 | |
| HK1246718A1 (zh) | 用於治疗囊性纤维化的化合物 | |
| HK1098140B (en) | 9-substituted 8-oxoadenine compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |